ReviewImmunological reviews2018
Understanding B-cell activation and autoantibody repertoire selection in systemic lupus erythematosus: A B-cell immunomics approach.
Review in Immunological reviews, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed.
- Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial.Annals of the rheumatic diseases · 2024Trial
- B-cell landscape remodelling following dual BAFF/APRIL inhibition with telitacicept in lupus nephritis: extrafollicular axis clearance and its association with clinical response.Lupus science & medicine · 2026Article
- Efficacy and safety of telitacicept combined with standard of care in patients with proliferative lupus nephritis: a real-world retrospective study.Lupus science & medicine · 2026Article
- Cytomegalovirus-induced hemophagocytic lymphohistiocytosis revealing systemic lupus erythematosus: a case report.Annals of medicine and surgery (2012) · 2026Article
- B-cell subset changes and clinical predictors of telitacicept response in SLE patients with antiphospholipid antibody positivity: a prospective observational cohort study.Frontiers in immunology · 2026Observational
- Mapping organ-associated autoantigenic landscapes in systemic lupus erythematosus.Frontiers in immunology · 2026Review
- Stratification of systemic lupus erythematosus with IGHV4-34 in unswitched memory B cells.Rheumatology (Oxford, England) · 2025Article
- Telitacicept for systemic lupus erythematosus: protocol of a systematic review and meta-analysis.BMJ open · 2025Article
- The influence of the gut microbiota on B cells in autoimmune diseases.Molecular medicine (Cambridge, Mass.) · 2025Review
- Evaluation of the efficacy and safety of belimumab and telitacicept in patients with systemic lupus erythematosus: results from a retrospective, observational study.Clinical and experimental medicine · 2025Observational
- BAFF/APRIL expression-guided telitacicept therapy demonstrates superior efficacy in systemic lupus erythematosus patients: a real-world comparative study.Frontiers in medicine · 2025Article
- Aberrant B cell responses as drivers of autoantibody generation and epitope diversification in SLE pathogenesis.Frontiers in immunology · 2025Review
- Research paper efficacy and safety of telitacicept combined with standard therapy for lupus nephritis: a single-center real-world study.Frontiers in immunology · 2025Article
- Characterization of systemic lupus erythematosus subtypes using cluster analysis: insights from lymphocyte subpopulations.Clinical rheumatology · 2024Article
- Machine learning for precision diagnostics of autoimmunity.Scientific reports · 2024Article
- Autoimmune haemolytic anaemias.Nature reviews. Disease primers · 2024Review
- Maternal Helminth Infection Causes Dysfunctional B Cell Development in Male Offspring.Journal of immunology (Baltimore, Md. : 1950) · 2024Article
- Use of belimumab in treating patients with systemic lupus erythematosus: a single-center, real-world retrospective study.Arthritis research & therapy · 2024Article
- Addressing Technical Pitfalls in Pursuit of Molecular Factors That Mediate Immunoglobulin Gene Regulation.Journal of immunology (Baltimore, Md. : 1950) · 2024Article
- T cell expressions of aberrant gene signatures and Co-inhibitory receptors (Co-IRs) as predictors of renal damage and lupus disease activity.Journal of biomedical science · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Understanding antibody repertoires and in particular, the properties and fates of B cells expressing potentially pathogenic antibodies is critical to define the mechanisms underlying multiple immunological diseases including autoimmune and allergic conditions as well as transplant rejection. Moreover, an integrated knowledge of the antibody repertoires expressed by B cells and plasma cells (PC) of different functional properties and longevity is essential to develop new therapeutic strategies, better biomarkers for disease segmentation, and new assays to measure restoration of B-cell tolerance or, at least, of normal B-cell homeostasis. Reaching these goals, however, will require a more precise phenotypic, functional and molecular definition of B-cell and PC populations, and a comprehensive analysis of the antigenic reactivity of the antibodies they express. While traditionally hampered by technical and ethical limitations in human experimentation, new technological advances currently enable investigators to address these questions in a comprehensive fashion. In this review, we shall discuss these concepts as they apply to the study of Systemic Lupus Erythematosus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.